Abstract
Alzheimer’s Disease (AD) is a highly prevalent neurodegenerative disorder. Despite increasing evidence of important metabolic dysregulation in AD, the underlying metabolic changes that may impact amyloid plaque formation are not understood, particularly for late onset AD. This study analyzed genome-wide association studies (GWAS), transcriptomics and proteomics data obtained from several data repositories to obtain differentially expressed (DE) multi-omics elements in mouse models of AD. We characterized the metabolic modulation in these datasets using gene ontology, and transcription factor, pathway and cell-type enrichment analysis. A predicted lipid signature was extracted from genome-scale metabolic networks (GSMN) and subsequently validated in a lipidomic dataset derived from cortical tissue of ABCA7-null mice, a mouse model of one of the genes associated with late onset AD. Moreover, a metabolome-wide association study (MWAS) was performed to further characterize the association between dysregulated lipid metabolism in human blood serum and AD.
We found 203 DE transcripts, 164 DE proteins and 58 DE GWAS-derived mouse orthologs associated with significantly enriched metabolic biological processes. Lipid and bioenergetics metabolic pathways were significantly over-represented across the AD multi-omics datasets. Microglia and astrocytes were significantly enriched in the lipid-predominant AD-metabolic transcriptome. We also extracted a predicted lipid signature that was validated and robustly modelled class separation in the ABCA7 mice cortical lipidome, with 11 of these lipid species exhibiting statistically significant modulations. MWAS revealed 298 AD single nucleotide polymorphisms (SNP)-metabolite associations, of which 70% corresponded to lipid classes.
These results support the importance of lipid metabolism dysregulation in AD and highlight the suitability of mapping AD multi-omics data into GSMNs to identify metabolic alterations.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Medical Research Council UK, the UK Dementia Research Institute, National Institute for Health Research (NIHR) and Imperial Biomedical Research Centre.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval for access to the Airwave cohort was granted following application to the access committee via the Dementia Platform UK (https://portal.dementiasplatform.uk/). Access to the RS cohort was granted following access to the Management Committee and conducted under approval from the Ministry of Health, Welfare and Sport of the Netherlands. This information is included in the manuscript.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
We reference all data used on mouse studies which is freely available through omics repositories. These links are provided in the text. In addition, ethical approval for access to the Airwave cohort was granted following application to the access committee via the Dementia Platform UK (https://portal.dementiasplatform.uk/). Access to the RS cohort was granted following access to the Management Committee and conducted under approval from the Ministry of Health, Welfare and Sport of the Netherlands.
Abbreviations
- Airwave
- Airwave Health Monitoring Study
- AD
- Alzheimer’s Disease
- Aβ
- amyloid-beta
- APP
- amyloid-precursor protein
- ABCA7
- ATP-binding-cassette subfamily-A member-7 gene
- APOE
- apolipoprotein epsilon
- ChEA3
- ChIP-X enrichment analysis 3
- DAVID
- database for annotation, visualization and integrated discovery
- DE
- differentially expressed
- EWCE
- expression weighted cell-type enrichment
- FDR
- false discovery rate
- FC
- fold change
- GEO
- gene expression omnibus
- GRCh37
- genome reference consortium-human build-37
- GSMN
- genome-scale metabolic networks
- GWAS
- genome-wide association studies
- IGAP
- international genomics of Alzheimer’s cohorts
- iTRAQ
- isobaric tag for relative and absolute quantification
- KO
- knock-out
- MAGMA
- multi-marker analysis of genomic annotation
- MWAS
- metabolome-wide association study
- NMR
- nuclear magnetic resonance
- OPLS-DA
- orthogonal projections to latent structures-discriminant analysis
- PQN
- probabilistic quotient normalization
- PRIDE
- protein identification database
- RP-UPLC-MS
- reverse-phase ultraperformance liquid chromatography-mass spectrometry
- RS
- Rotterdam study
- SAM
- significance analysis of microarray
- SNPs
- single nucleotide polymorphisms
- S.D.f.M
- standard deviation from the bootstrapped mean
- SREBP2
- sterol regulatory element binding protein 2
- TF
- transcription factor
- TREM2
- triggering receptor expressed on myeloid cells-2
- UPLC-MS
- ultraperformance liquid chromatography-mass spectrometry
- VIP
- variable influence of projection
- WT
- wild-type
